Idera Pharmaceuticals Inc.

2.48-0.0800-3.13%Vol 268.31K1Y Perf -11.25%
Sep 22nd, 2020 16:00 DELAYED
BID2.48 ASK2.50
Open2.55 Previous Close2.56
Pre-Market- After-Market-
 - -%  - -%
Target Price
7.00 
Analyst Rating
Strong Buy 1.00
Potential %
182.26 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★+     42.24
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Market Cap87.29M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
72.93 
Earnings Date
4th Nov 2020

Today's Price Range

2.222.55

52W Range

0.81003.10

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.40%
1 Month
28.50%
3 Months
34.05%
6 Months
96.83%
1 Year
-11.25%
3 Years
-86.10%
5 Years
-91.93%
10 Years
-90.75%

TickerPriceChg.Chg.%
IDRA2.48-0.0800-3.13
AAPL111.811.73001.57
GOOG1 465.4634.30002.40
MSFT207.424.88002.41
XOM35.53-0.9000-2.47
WFC23.65-0.3900-1.62
JNJ144.21-0.8900-0.61
FB254.756.60002.66
GE6.25-0.1000-1.57
JPM94.27-1.0400-1.09
ProfitabilityValueIndustryS&P 500US Markets
-
-4 034.70
-4 027.10
-8 000.10
-
RevenueValueIndustryS&P 500US Markets
0.00
0.00
-40.82
35.11
Earnings HistoryEstimateReportedSurprise %
Q02 2020-0.36-0.2627.78
Q01 2020-0.40-0.43-7.50
Q04 2019--0.40-
Q03 2019-0.47-0.3917.02
Q02 2019-0.42-0.397.14
Q01 2019-0.46-0.4013.04
Q04 2018-0.49-0.458.16
Q03 2018-0.56-0.4617.86
Earnings Per EndEstimateRevision %Trend
9/2020 QR-0.2116.00Positive
12/2020 QR-0.2119.23Positive
12/2020 FY-1.0222.73Positive
12/2021 FY-0.60-20.00Negative
Next Report Date4th Nov 2020
Estimated EPS Next Report-0.21
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume268.31K
Shares Outstanding35.20M
Trades Count1.53K
Dollar Volume657.08K
Avg. Volume265.87K
Avg. Weekly Volume304.10K
Avg. Monthly Volume324.65K
Avg. Quarterly Volume342.06K

Idera Pharmaceuticals Inc. (NASDAQ: IDRA) stock closed at 2.48 per share at the end of the most recent trading day (a -3.13% change compared to the prior day closing price) with a volume of 268.31K shares and market capitalization of 87.29M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 36 people. Idera Pharmaceuticals Inc. CEO is Vincent J. Milano.

The one-year performance of Idera Pharmaceuticals Inc. stock is -11.25%, while year-to-date (YTD) performance is 36.26%. IDRA stock has a five-year performance of -91.93%. Its 52-week range is between 0.81 and 3.1, which gives IDRA stock a 52-week price range ratio of 72.93%

Idera Pharmaceuticals Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 1.29, a price-to-sale (PS) ratio of 41.75, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -174.64%, a ROC of -489.41% and a ROE of -518.02%. The company’s profit margin is -%, its EBITDA margin is -4 027.10%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Idera Pharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Idera Pharmaceuticals Inc.’s next earnings report date is 04th Nov 2020.

The consensus rating of Wall Street analysts for Idera Pharmaceuticals Inc. is Strong Buy (1), with a target price of $7, which is +182.26% compared to the current price. The earnings rating for Idera Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Idera Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Idera Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 20.30, ATR14 : 0.21, CCI20 : 81.88, Chaikin Money Flow : -0.07, MACD : 0.13, Money Flow Index : 73.98, ROC : 26.53, RSI : 60.86, STOCH (14,3) : 68.24, STOCH RSI : 0.54, UO : 58.56, Williams %R : -31.76), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Idera Pharmaceuticals Inc. in the last 12-months were: Bryant D. Lim (Sold 1 603 shares of value $2 854 ), John J. Kirby (Sold 1 822 shares of value $3 244 ), Jonathan Michael Yingling (Sold 1 742 shares of value $3 101 ), Robert Fletcher (Sold 1 615 shares of value $2 875 ), Vincent J. Milano (Sold 3 006 shares of value $5 352 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Idera Pharmaceuticals Inc.

Idera Pharmaceuticals Inc is a clinical-stage biopharmaceutical company involved in the discovery, development, and commercialization of innovative therapeutics for oncology and rare diseases. The company has developed two distinct proprietary drug-discovery technology platforms: Toll-like receptor and third-generation antisense technology. The Toll-like receptor technology helped the company create synthetic oligonucleotide-based drug candidates. The 3GA technology is used to create drug candidates to turn off the RNA messengers associated with genes causing various diseases.

CEO: Vincent J. Milano

Teplephone: +1 484 348-1600

Address: 505 Eagleview Boulevard, Exton 19341, PA, USA

Number of employees: 36

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

50%50%

Bearish Bullish

41%59%

News

Stocktwits